Gain-of-function mutations in CTNNB1 in HCC inhibit β-catenin phosphorylation and subsequent breakdown, leading to the activation of the Wnt-β-catenin signaling pathway, which then enhances cellular growth, and movement [201, 205]. Here, CTNNB1 is linked to hepatocellular carcinoma.